Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WoundSeal is a non-prescription topical hemostatic powder designed to stop minor external bleeding rapidly. It consists of a hydrophilic polymer and potassium ferrate. Upon application to a bleeding wound and with manual pressure, the hydrophilic polymer absorbs blood and exudates, while potassium ferrate reacts with blood proteins to form an an occlusive seal or "instant scab" over the wound. This seal stops bleeding quickly—often within 30 seconds—and protects the wound as it heals beneath the barrier. The product does not rely on the body's natural clotting mechanisms, making it suitable for patients on anticoagulants or those with clotting disorders. It is non-toxic, hypoallergenic, not biologically derived, and does not act as a vasoconstrictor or cauterizing agent. Indications include cuts, skin tears, punctures, avulsions, biopsies, excisions (including Mohs micrographic surgery), nail avulsions, dialysis access sites, nosebleeds (with applicator), and other minor external wounds[1][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on WoundSeal.